WO1983000702A1 - Enhancement of expression of protein synthesis in e. coli - Google Patents

Enhancement of expression of protein synthesis in e. coli Download PDF

Info

Publication number
WO1983000702A1
WO1983000702A1 PCT/US1982/001075 US8201075W WO8300702A1 WO 1983000702 A1 WO1983000702 A1 WO 1983000702A1 US 8201075 W US8201075 W US 8201075W WO 8300702 A1 WO8300702 A1 WO 8300702A1
Authority
WO
WIPO (PCT)
Prior art keywords
plasmid
gene
cells
dominant
allele
Prior art date
Application number
PCT/US1982/001075
Other languages
French (fr)
Inventor
Inc. University Patents
Alvin Markovitz
Barbara A. Zehnbauer
Joyce M. Schoemaker
Marc F. Charette
Original Assignee
University Patents Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Patents Inc filed Critical University Patents Inc
Publication of WO1983000702A1 publication Critical patent/WO1983000702A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli

Definitions

  • the present invention relates generally to genetic engineering and more specifically to use of recombinant DNA techniques to secure expression of protein synthesis in selected unicellular organisms.
  • microorganisms have provided a source of commercially significant products such as antibiotics, enzymes and other biologically active proteins, alcohols and the like.
  • Bacteria and yeasts have been the subject of intensive research effort which has had as its goal the enhancement of the cellular and extracellular yield o •*f such commercial products by naturally-occurring and artificially mutated (e.g. , radiation treated) strains of organ- isms. While manipulation of fermentation and product harvesting process parameters can frequently bring about dramatic increases in product yield for selected strains, it is most frequently the case that no degree of modification of culture and isolation conditions will result in enhancing an organism's "expression" of a particular product as evidenced by increased product yields.
  • U.S. Letters Patent No. 4,237,224 to Cohen, et al. relates to transformation of procaryotic unicellular host organisms with "hybrid" viral or circular plasmid DNA which includes exogenous DNA sequences.
  • the procedures of the Cohen, et ⁇ al. patent first involve manufacture of a transformation vector by enzymatically cleaving viral or circular plasmid DNA to form linear DNA strands. Selected foreign DNA strands are also prepared in linear form through use of similar enzymes.
  • the linear viral or plasmid DNA is incubated with foreign DNA in the presence of ligating enzymes capable of effecting a restoration process, and "hybrids" are formed which include the selected foreign DNA segment "spliced" into the viral or circular DNA plasmid. Transformation of -compatible host unicellular organisms with the hybrid vector and propogation of transformant cells results in' the formation of multiple copies of the foreign DNA in the host cell population. In some instances, the desired result is simply the amplification of the foreign DNA and the "product" harvested is DNA. More frequently, the goal of transformation is the expression by the host cells of the foreign DNA in the form of large scale synthesis of isolatable quantities of, e.g. , commercially significant protein and polypeptide fragments coded for by the foreign DNA.
  • marker gene sequences Another manipulative "tool” largely re ⁇ sponsible for successes in transformation of pro- caryotic cells is the use of selectable "marker” gene sequences. Briefly put, hybrid vectors are employed which contain, in addition to the desired foreign DNA, one or more DNA sequences which code for expression of a phenotypic trait capable of distinguishing transformed "from non-transformed host cells. Typical marker gene sequences are those which allow a transformed procaryotic cell to survive and propogate in a culture medium containing metals, antibiotics, and like components which would kill or severly inhibit propagation of non-transformed host cells.
  • endogenous and exogenous gene directed expression of protein synthesis by Escherichia coli cells is en- hanced by transformation of the cells to incorporate one or more copies of a dominant mucoid mutant allele of capR (Ion) gene, preferably the capR9 allele.
  • the mutant capR9 allele is publicly available as a com ⁇ ponent of the DNA plasmid, pBZ20lM9 (A.T.C.C. Plasmid No. 40041) which plasmid provides a presently pre ⁇ ferred vehicle for effecting ⁇ __ coli cell transforma ⁇ tion according to the invention.
  • the ex ⁇ pression of protein synthesis by endogenous genes of naturally occurring and mutant E ⁇ _ coli strains is enhanced by the simple transformation of cells with an E. coli plasmid such as A.T.C.C. Plasmid No. 40041 which includes the capR9 allele.
  • E. coli plasmid such as A.T.C.C. Plasmid No. 40041 which includes the capR9 allele.
  • the same procedure is available to enhance expression of protein synthe- sis in E_ ⁇ coli strains which have had exogenous, protein synthesis directing, genes stably incorporated into chromosomes.
  • E ⁇ _ coli strains which have been transformed with a first vector including a selected exogenous DNA sequence coding for a protein of interest are addi ⁇ tionally transformed with a plasmid providing the capR9 allele such as A.T.C.C. Plasmid No. 40041.
  • the capR9 allele may be incorporated on the same hybrid vector as the selected exogenous DNA sequence and both genes (possibly under the control of the same promotor) may be simultaneously introduced into the ⁇ ]_-_ coli host, with verification of the transformation secured through monitoring for a single marker gene.
  • the term “protein” shall mean and include not only whole functional proteins, but also polypeptides. "Enhancement of expression” of protein synthesis shall designate increasing the net quantity of a selected protein isolatable from a system, whether such increase is attributable to an increase in the amount of the protein synthesized by cells in the system or to an increase in synthesized intact protein remaining available for harvesting from the system.
  • the term “genetically transforming” shall mean effecting the stable incorpo ⁇ ration of 'a selected DNA sequence into an E ⁇ coli cell, whether by way of insertion into chromosomal DNA or by way of incorporation of a vector including the selected sequence.
  • the present invention has its origins, in part, in work commenced over fifteen years ago by co-inventor Markovitz and his co-workers. See, e.g. , Markovitz, et al., P.N.A.S. 5_1, 239 (1964) and 54_ 1084 (1965) . Briefly stated, this work dealt with mutants of an E ⁇ coli K-12 regulator gene, "capR” (also referred to in the art as the "Ion” gene) which controls the synthesis of capsular polysaccharide and the enzymes involved in capsular polysaccharide synthesis.
  • capR also referred to in the art as the "Ion” gene
  • mutant capR phenotypes include: failure to lysogenize temperate phages [Takano, P.N.A.S. , 68, pp. 1469-1473 (1971)]; increased sensi ⁇ tivity to radiation [Howard-Flanders, et al., Genetics, 49, pp. 237-246 (1964) and Adler, et al. , J. Bacteriol. , 87, pp. 720-726 (1964)]; abnormal cell division [Walker, et al. , Mol,Gen.Genet. , 108, pp. 1296-1303 (1970) and Gayda, et al. , J. Bacteriol., 127, pp.
  • O PI involves derepression of the galETK operon and that the mucoid phenotype is not, by itself, responsible for other capR mutant phenotypes.
  • Gal " derivatives of capR mutants, for example, result in nonmucoid colonies that continue to exhibit the remaining capR mutant phenotypes. [See, e.g. - Markovitz (1977) supra and Gottesman, e_t al. , J. Bacteriol. , 133, pp. 844-851 (1978)] .
  • One particular dominant mucoid allele of the capR gene, called capR9 is of special significance to the present invention.
  • capR9 strains exhibit all of the standard phenotypes (mucoid appearance, radiation sensitivity, etc.) .
  • the mutant (mucoid) phenotype was dominant to the wild type (nonmucoid) phenotype. See, e.g. , Markovitz, et al. , P.N.A.S. , 4, pp.
  • capR9 When the capR9 was present in multiple copies (perhaps 2-3 times for an F' plasmid) , the defective subunits would dominate in the oligomer and the mutant phenotype would be expressed. This would be reversed when the wild type is in multiple copies. It is believed that the capR9 allele codes for a shortened polypeptide product because its phenotypes are partially reversed by ochre (nonesense) suppressors [Markovitz, et al. J.Bacteriol. , 94, pp. 338-395 (1967) and Markovitz (1977) supra.]
  • E__ coli strain CSR603 which displays the inability to repair damage to DNA from exposure to ultraviolet light.
  • the cells are transformed by plasmids which represent a smaller target for DNA damage and then irradiated with ultra ⁇ violet light, they are generally capable of expressing those proteins coded by the plasmid, but not by the chromosome.
  • Test cells were transformed with both plasmid pBZ201 containing the wild type capR gene and pBZ20lM9 which contained the capR9 mutation. The transformation procedure employed was as described in
  • 35 S-methionine was added to the culture medium con ⁇ taining the UV-treated cells , and .proteins harvested from the cells were thereafter subjected to electrophoretic analysis.
  • the control CSR603 cells showed no labelled proteins.
  • Cells transformed with the wild type plasmid displayed two distinct proteins, one of which is characteristic of the wild type capR gene coded by the plasmid.
  • CSR603 cells transformed with the capR9 plasmid displayed not only a labelled protein characteristic of the capR9 gene but also a wide array of unidentified cellular proteins not present in either the control GSR603 cells or those transformed with the pBZ201 plasmid.
  • Plasmid PEX2 is derived from plasmid pRI-11 which contains the rat proinsulin gene [Chan, et al. ,P.N.A.S. , 76, pp. 5036-5040 (1979)]. Plasmid PEX2 was engineered to contain the lac prompter DNA in ⁇ serted into the appropriate position of pRI-11 so that expression of synthesis of rat proinsulin messenger RNA and protein should occur. Radioimmunoassay [Rubenstein, et al. , Diabetes, 19, pp. 546-553 (1970)] for rat proinsulin product of cultured growth of the transformed cells detected no proinsulin product,
  • the "unsuccessful" transformant cells were thereafter further transformed with the capR9 plasmid, pBZ20lM9 (A.T.C.C.Plasmid 40041). Products of cells transformed with the capR9 allele were subjected to radioimmunoassay as above and revealed the presence of about 60 nanograms per liter of rat proinsulin which is the equivalent of approximately 100 molecules per cell.
  • capR capsular polysaccharide
  • gene such as capR9
  • Example 2 numerous alternatives to the Example 2 procedure of effecting a first transformation with a plasmid incorporating the exogenous gene and a second trans ⁇ formation with a vector incorporating the capR9 gene exist.
  • the mutant allele could be directly incorpor- ated into the chromosome.
  • a concurrent transformation of the E_ j _ coli host with both the selected exogenous gene and the capR9 gene could be made using a single hybrid vector incorporating both genes.
  • DNA plasmid pBZ20lM9 may itself be further hybridized, for example, to incorporate a selected exogenous gene coding for a protein of interest.
  • protein coded for by the dominant mucoid mutant gene functions to bind with and stabilize nucleic acids (specifically messenger RNA) in the host cell, preventing 'degradation and hence allowing for enhanced expression in the form of enhanced protein formation.
  • nucleic acids specifically messenger RNA
  • Such a theory provides a reasonable explanation for the results obtained in Example 1 above. More partic ⁇ ularly, the appearance of significant quantities of unidentified labelled protein in irradiated test cells could be due to the capR9 protein binding to m-RNA formed prior to irradiation (and chromosomal inacti- vation) . The m-RNA so stabilized and protected from degradation would be available to operate as a translational template for synthesis of protein incorporating the labelled methionine.
  • An alternative theory of operation of the invention has as its basis the ability of the protein coded for by the mutant allele to diminish activity of the wild type capR protein in degrading such proteins formed by the host cell which may be recognized in the cell as "foreign". This theory provides an explana ⁇ tion for the remarkable results obtained in Example 2 above.
  • capR9 shows no ATP-dependent protease activity, practically no ATPase activity in the presence of casein, and greatly reduced DNA-dependent ATPase activity.
  • I_n vitro experiments using mixtures of both capR and capR9 protein reveal significant diminution of wild type protein protease activity. Whether, in vivo, the mutant protein binds to (and represses activity of) the wild type protein or whether the putatively inactive mutant protein simply competes more effectively for binding sites than the wild type protein, the net result appears* to be enhanced expression of certain proteins in the form of diminished degradation thereof by the protease products of the wild type capR gene.
  • the overall result is enhanced expression of protein synthesis in terms of greater net quantities of isolatable products of exogenous and endogenous gene directed protein synthesis.
  • the present invention additionally compre ⁇ hends improvements in prior methods for securing production, in 1__ coli host cells, of protein coded for by exogenous genes, which improvements comprise employing E ⁇ _ coli host cells which contain a chor osomal mutation in the capsular polysaccharide, capR (Ion) , gene. While preferred methods involve use of E ⁇ _ coli cells having the above-noted dominant mucoid mutant allele (especially the capR9 allele) , also comprehended is the use of cells carrying other capR mutations, including recessive mutations. An example of the practice of this improved methodology is provided by the following description of work performed by collaborators Donald F.
  • Radioimmunoassays for rat proinsulin were carried out according to the procedures noted in Example 2. No rat proinsulin production was detected in the host cells of the first experiment. Rat proinsulin was detected in the host cells of the second experiment, wherein the host strain carried a mutation in the capR

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Endogenous and exogenous gene directed expression of protein synthesis in Escherichia Coli is enhanced by transformation to incorporate a dominant mucoid mutant allele of the capR (lon) gene, preferably through use of the DNA plasmid, pBZ201M9 (A.T.C.C. Plasmid No. 40041) which carries the capR9 mutant allele.

Description

Description
ENHANCEMENT OF EXPRESSION OF PROTEIN SYNTHESIS IN E. COLI
BACKGROUND
The present invention relates generally to genetic engineering and more specifically to use of recombinant DNA techniques to secure expression of protein synthesis in selected unicellular organisms.
For many years, microorganisms have provided a source of commercially significant products such as antibiotics, enzymes and other biologically active proteins, alcohols and the like. Bacteria and yeasts have been the subject of intensive research effort which has had as its goal the enhancement of the cellular and extracellular yield o •*f such commercial products by naturally-occurring and artificially mutated (e.g. , radiation treated) strains of organ- isms. While manipulation of fermentation and product harvesting process parameters can frequently bring about dramatic increases in product yield for selected strains, it is most frequently the case that no degree of modification of culture and isolation conditions will result in enhancing an organism's "expression" of a particular product as evidenced by increased product yields. A focus of genetic engineering in the recent past has been the use of recombinant DNA methodologies for the purification and amplification of genetic material. U.S. Letters Patent No. 4,237,224 to Cohen, et al. , for example, relates to transformation of procaryotic unicellular host organisms with "hybrid" viral or circular plasmid DNA which includes exogenous DNA sequences. The procedures of the Cohen, et^ al. patent first involve manufacture of a transformation vector by enzymatically cleaving viral or circular plasmid DNA to form linear DNA strands. Selected foreign DNA strands are also prepared in linear form through use of similar enzymes. The linear viral or plasmid DNA is incubated with foreign DNA in the presence of ligating enzymes capable of effecting a restoration process, and "hybrids" are formed which include the selected foreign DNA segment "spliced" into the viral or circular DNA plasmid. Transformation of -compatible host unicellular organisms with the hybrid vector and propogation of transformant cells results in' the formation of multiple copies of the foreign DNA in the host cell population. In some instances, the desired result is simply the amplification of the foreign DNA and the "product" harvested is DNA. More frequently, the goal of transformation is the expression by the host cells of the foreign DNA in the form of large scale synthesis of isolatable quantities of, e.g. , commercially significant protein and polypeptide fragments coded for by the foreign DNA.
OWH The success of procedures such as described by Cohen et al. is due in large part to the ready availability of restriction endonuclease enzymes which facilitate the site-specific cleavage of both the unhybridized DNA vector and, e.g. , eukaryotic DNA strands containing the foreign sequences of interest. Cleavage in a manner providing for the formation of complementary "ends" on the linear DNA strands greatly enhances the likelihood of functional incorporation of the foreign DNA into the reconstituted vector formed by ligating enzyme treatment. Verification of hybrid formation is facilitated by chromatographic techniques which can, for example, distinguish hybrid plasmids from non-hybrids on the basis of molecular weight. Other useful verification techniques involve radioact¬ ive DNA hybridization.
Another manipulative "tool" largely re¬ sponsible for successes in transformation of pro- caryotic cells is the use of selectable "marker" gene sequences. Briefly put, hybrid vectors are employed which contain, in addition to the desired foreign DNA, one or more DNA sequences which code for expression of a phenotypic trait capable of distinguishing transformed "from non-transformed host cells. Typical marker gene sequences are those which allow a transformed procaryotic cell to survive and propogate in a culture medium containing metals, antibiotics, and like components which would kill or severly inhibit propagation of non-transformed host cells. Reports abound concerning successful trans¬ formation of host microorganisms such as Escherichia coli with common circular DNA plasmids such as pBR322 which has been hybridized to incorporate exogenous procaryotic or eukaryotic genes. Relatively large quantities of the protein products coded for by the foreign genes can often be isolated from the trans- formant cells or from the culture medium in which the cells are propogated.
Rather expectedly, the literature provides few details of the numerous unsuccessful attempts at securing desired expression of foreign gene directed protein synthesis using standard host/vector method¬ ologies. While is some instances transformation "failures" are simply the result of defective hybrid formation, it is nonetheless frequently the case that an "unsuccessful" vector is verified as including all portions of a foreign gene sequence that are otherwise necessary for directing synthesis of the desired protein product. Similarly, the lack of success in some experiments can be attributed to a generalized incompatibility between host and vector. In many cases, however, stable incorporation of the vector (accompanied by extensive replication and expression of marker gene phenotype) does take place, but ex¬ pression of desired protein synthesis does not. The failure of host microorganisms to express proteins coded for by foreign DNA sequences may also be a problem in recombinant DNA methodologies involving direct incorporation of exogenous DNA into chromosomes of microorganisms. While chromatographic and radioisotopic DNA hybridization studies might verify incorporation of entire genes (including necessary promoter and leader sequences) into host genomes, there may be no corresponding expression of the protein coded for by the gene. , Among the hypotheses advanced in explanation for the failure of otherwise fully operational trans¬ formation systems to provide the desired yields of exogenous gene directed protein are: (1) interference by host cell constituents in transcription and/or
OMPI translation of the foreign DNA; and (2) interference by host cell constituents in the accumulation of readily isolatable quantities of gene products in the host cells. As indicated by the above, therefore, there exists a general need in the art for methods and materials which will serve to enhance the expression of endogenous gene directed protein synthesis in naturally occurring and mutant microorganisms as well as expression of exogenous gene directed protein synthesis in microorganisms which have been the subject of transformations with exogenous DNA by recombinant DNA methodologies.
-^TRE
OMPI °
BRIEF SUMMARY
According to the present invention, endogenous and exogenous gene directed expression of protein synthesis by Escherichia coli cells is en- hanced by transformation of the cells to incorporate one or more copies of a dominant mucoid mutant allele of capR (Ion) gene, preferably the capR9 allele. The mutant capR9 allele is publicly available as a com¬ ponent of the DNA plasmid, pBZ20lM9 (A.T.C.C. Plasmid No. 40041) which plasmid provides a presently pre¬ ferred vehicle for effecting Ε__ coli cell transforma¬ tion according to the invention.
In one aspect of the invention, the ex¬ pression of protein synthesis by endogenous genes of naturally occurring and mutant E^_ coli strains is enhanced by the simple transformation of cells with an E. coli plasmid such as A.T.C.C. Plasmid No. 40041 which includes the capR9 allele. The same procedure is available to enhance expression of protein synthe- sis in E_^ coli strains which have had exogenous, protein synthesis directing, genes stably incorporated into chromosomes.
According to another - aspect of the invention, E^_ coli strains which have been transformed with a first vector including a selected exogenous DNA sequence coding for a protein of interest are addi¬ tionally transformed with a plasmid providing the capR9 allele such as A.T.C.C. Plasmid No. 40041. Further, the capR9 allele may be incorporated on the same hybrid vector as the selected exogenous DNA sequence and both genes (possibly under the control of the same promotor) may be simultaneously introduced into the Ε]_-_ coli host, with verification of the transformation secured through monitoring for a single marker gene.
Other aspects and advantages of the present invention will be apparent from the following detailed description.
DETAILED DESCRIPTION
As used herein, the term "protein" shall mean and include not only whole functional proteins, but also polypeptides. "Enhancement of expression" of protein synthesis shall designate increasing the net quantity of a selected protein isolatable from a system, whether such increase is attributable to an increase in the amount of the protein synthesized by cells in the system or to an increase in synthesized intact protein remaining available for harvesting from the system. As used herein, the term "genetically transforming" shall mean effecting the stable incorpo¬ ration of 'a selected DNA sequence into an E^ coli cell, whether by way of insertion into chromosomal DNA or by way of incorporation of a vector including the selected sequence.
The present invention has its origins, in part, in work commenced over fifteen years ago by co-inventor Markovitz and his co-workers. See, e.g. , Markovitz, et al., P.N.A.S. 5_1, 239 (1964) and 54_ 1084 (1965) . Briefly stated, this work dealt with mutants of an E^ coli K-12 regulator gene, "capR" (also referred to in the art as the "Ion" gene) which controls the synthesis of capsular polysaccharide and the enzymes involved in capsular polysaccharide synthesis.
Cells containing certain dominant mutant forms of the capR gene were noted to display a dis¬ tinct "mucoid" phenotype when grown on minimal medium. The mucoid appearance was determined to result from overproduction of capsular polysaccharide, which is composed of glucose, galactose, fucose, glucruonic acid, acetate, and pyruvate. [See, Sutherland, Biochem. J. , 115, pp. 935-945 (1969).] The over¬ production of capsular polysaccharide observed in capR mutants has been attributed to derepression of ten enzymes in at least four spatially separated operons concerned with production of the polysaccharide capsule. [See, Markovitz, at pp, 415-462 in Surface Carbohydrates of the Procaryotic Cell (Sutherland, ed.) Academic Press, New York (1977).]
Other mutant capR phenotypes include: failure to lysogenize temperate phages [Takano, P.N.A.S. , 68, pp. 1469-1473 (1971)]; increased sensi¬ tivity to radiation [Howard-Flanders, et al., Genetics, 49, pp. 237-246 (1964) and Adler, et al. , J. Bacteriol. , 87, pp. 720-726 (1964)]; abnormal cell division [Walker, et al. , Mol,Gen.Genet. , 108, pp. 1296-1303 (1970) and Gayda, et al. , J. Bacteriol., 127, pp. 1208-1216 (1976)]; and reduced degradation of certain normal [Gayda, et al., Mo1.Gen.Genet. , 175, pp. 325-332 (1979)] and abnormal proteins (Bukhari,et al. ,Nature New Biol. (London) , 243, -pp. 238-241 (1973) and Shineberg, et al^. , J. Bacteriol., 116, pp. 1469-1471 (1973)], as well as lambda viral protein [Gottesman, et al., Cell, 24, pp. 225-233 (1981)].
Studies of the mucoid phenotype indicate that overproduction of capsular polysaccharide
f JRE^
O PI involves derepression of the galETK operon and that the mucoid phenotype is not, by itself, responsible for other capR mutant phenotypes. Gal derivatives of capR mutant phenotypes. Gal" derivatives of capR mutants, for example, result in nonmucoid colonies that continue to exhibit the remaining capR mutant phenotypes. [See, e.g. - Markovitz (1977) supra and Gottesman, e_t al. , J. Bacteriol. , 133, pp. 844-851 (1978)] . One particular dominant mucoid allele of the capR gene, called capR9, is of special significance to the present invention. In a haploid state, capR9 strains exhibit all of the standard phenotypes (mucoid appearance, radiation sensitivity, etc.) . However, in partial diploid studies when the capR9 allele was placed on a plasmid with the capR allele on the chromosome, the mutant (mucoid) phenotype was dominant to the wild type (nonmucoid) phenotype. See, e.g. , Markovitz, et al. , P.N.A.S. , 4, pp. 1084-1091 (1965) for discussion of the capR9 allele (referred to therein as C-9) as well as other dominant mutant mucoid alleles (referred to as C-62 and C-66) . This mutant-phenotype dominance was reversed when the capR gene was on the plasmid and the capR9 mutation was on the chro o'some. These results were interpreted as indicating that the capR (Ion) gene product acts as an oligo er composed of identical εubunits. According to this hypothesis, the capR9 gene would code for a defective subunit. When the capR9 was present in multiple copies (perhaps 2-3 times for an F' plasmid) , the defective subunits would dominate in the oligomer and the mutant phenotype would be expressed. This would be reversed when the wild type is in multiple copies. It is believed that the capR9 allele codes for a shortened polypeptide product because its phenotypes are partially reversed by ochre (nonesense) suppressors [Markovitz, et al. J.Bacteriol. , 94, pp. 338-395 (1967) and Markovitz (1977) supra.]
EXAMPLE 1
An illustrative example of the methods of the invention which result in the enhanced expression of endogenous gene directed protein synthesis is provided in the publication of co-inventors Zehnbauer, and Markovitz appearing in J. Bacteriol. - 143, pp. 852-863 (published August 27, 1980).
Briefly summarized the method therein described involved use of E__ coli strain CSR603 which displays the inability to repair damage to DNA from exposure to ultraviolet light. When the cells are transformed by plasmids which represent a smaller target for DNA damage and then irradiated with ultra¬ violet light, they are generally capable of expressing those proteins coded by the plasmid, but not by the chromosome. Test cells were transformed with both plasmid pBZ201 containing the wild type capR gene and pBZ20lM9 which contained the capR9 mutation. The transformation procedure employed was as described in
Avni, et al. J. Bacteriol., 129, pp. 358-366 (1977).
(DNA plasmid pBZ20lM9 has been deposited by applicants with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 and the plasmid has been assigned A.T.C.C. Plasmid No. 40041.) Non-transformed (control) CSR603 cells together with cells transformed with plasmid pBZ201 and cells transformed with plasmid pBZ20lM9 were all exposed to ultraviolet light. Radioactive labelled
35 S-methionine was added to the culture medium con¬ taining the UV-treated cells , and .proteins harvested from the cells were thereafter subjected to electrophoretic analysis.
The control CSR603 cells showed no labelled proteins. Cells transformed with the wild type plasmid displayed two distinct proteins, one of which is characteristic of the wild type capR gene coded by the plasmid. CSR603 cells transformed with the capR9 plasmid displayed not only a labelled protein characteristic of the capR9 gene but also a wide array of unidentified cellular proteins not present in either the control GSR603 cells or those transformed with the pBZ201 plasmid.
EXAMPLE 2
An illustrative example of practice of the invention to effect enhanced expression of an exogenous gene is provided by the following descrip¬ tion of work performed in collaboration with the inventors by Donald F. Steiner and Shu Jin Chan of the Department of Biochemistry of The University of Chicago.
E^ coli K-12, strain JA221 (r^ derivative of strain C600 containing trpAE5, leu-6, recA) was transformed in the usual fashion to contain plasmid PEX2. Plasmid PEX2 is derived from plasmid pRI-11 which contains the rat proinsulin gene [Chan, et al. ,P.N.A.S. , 76, pp. 5036-5040 (1979)]. Plasmid PEX2 was engineered to contain the lac prompter DNA in¬ serted into the appropriate position of pRI-11 so that expression of synthesis of rat proinsulin messenger RNA and protein should occur. Radioimmunoassay [Rubenstein, et al. , Diabetes, 19, pp. 546-553 (1970)] for rat proinsulin product of cultured growth of the transformed cells detected no proinsulin product,
O PI although the assay procedure was capable of detecting as little as 0.5 nanograms per liter of culture.
The "unsuccessful" transformant cells were thereafter further transformed with the capR9 plasmid, pBZ20lM9 (A.T.C.C.Plasmid 40041). Products of cells transformed with the capR9 allele were subjected to radioimmunoassay as above and revealed the presence of about 60 nanograms per liter of rat proinsulin which is the equivalent of approximately 100 molecules per cell.
While the first of the above two illustra¬ tive examples demonstrates operability of methods of the invention for enhancement of expression of endogenous gene directed protein synthesis in E^ coli strains by transformation to incorporate plasmid pBZ201M9 (A.T.C.C. No. 40041) , it will be apparent that any DNA plasmid or similar DNA vector (e.g. , bacteriophage DNA, which is frequently referred to as plasmid DNA in the context of cell transformation) may be suitably fashioned to incorporate the capR9 gene or other dominant mucoid mutant allele of capR, and that the resulting hybrid may be employed in practice of the invention. Plasmids providing either more or fewer copies than pBZ201 in transformed cells may be used.
In like manner, when a dominant mucoid mutant of the capsular polysaccharide, capR, gene such as capR9 is to be employed to enhance expression of protein synthesis in E^_ coli by an exogenous gene, numerous alternatives to the Example 2 procedure of effecting a first transformation with a plasmid incorporating the exogenous gene and a second trans¬ formation with a vector incorporating the capR9 gene exist. The mutant allele could be directly incorpor- ated into the chromosome. A concurrent transformation of the E_j_ coli host with both the selected exogenous gene and the capR9 gene could be made using a single hybrid vector incorporating both genes. DNA plasmid pBZ20lM9 may itself be further hybridized, for example, to incorporate a selected exogenous gene coding for a protein of interest.
While both of the above examples relate to isolation of protein directly from JE^ coli cells, it is contemplated that harvesting of the protein product of interest may be from the culture medium in which transformed T__ coli cells are propagated. Similarly, while both examples involve use of K-12 E_^ coli strains, the invention is equally applicable to other strains. The precise mode of operation of, e.g. , the capR9 gene, in enhancing expression of endogenous and exogenous gene directed protein synthesis is at present not fully elucidated. The proposed theories of operation noted below are therefore not intended to be limiting on the invention.
According to one theory of the invention, protein coded for by the dominant mucoid mutant gene functions to bind with and stabilize nucleic acids (specifically messenger RNA) in the host cell, preventing 'degradation and hence allowing for enhanced expression in the form of enhanced protein formation. Such a theory provides a reasonable explanation for the results obtained in Example 1 above. More partic¬ ularly, the appearance of significant quantities of unidentified labelled protein in irradiated test cells could be due to the capR9 protein binding to m-RNA formed prior to irradiation (and chromosomal inacti- vation) . The m-RNA so stabilized and protected from degradation would be available to operate as a translational template for synthesis of protein incorporating the labelled methionine.
An alternative theory of operation of the invention has as its basis the ability of the protein coded for by the mutant allele to diminish activity of the wild type capR protein in degrading such proteins formed by the host cell which may be recognized in the cell as "foreign". This theory provides an explana¬ tion for the remarkable results obtained in Example 2 above.
In the course of exhaustive analysis of the activities of the protein coded for by the wild type capR gene, it was determined that gene product activities included an ATP-hydrolysis-dependent protease activity, (i.e. , displayed in the presence of casein) , and a second ATPase activity stimulated by DNA. See, e.g. , Schoemaker, et al. , J. Bacteriol. , 147, pp. 46-56 (1981) and Zehnbauer, et al., P.N.A.S. , 78, pp. 2043-2047 (1981). The gene product of capR9, however, shows no ATP-dependent protease activity, practically no ATPase activity in the presence of casein, and greatly reduced DNA-dependent ATPase activity. I_n vitro experiments using mixtures of both capR and capR9 protein reveal significant diminution of wild type protein protease activity. Whether, in vivo, the mutant protein binds to (and represses activity of) the wild type protein or whether the putatively inactive mutant protein simply competes more effectively for binding sites than the wild type protein, the net result appears* to be enhanced expression of certain proteins in the form of diminished degradation thereof by the protease products of the wild type capR gene.
Thus, whether the presence of the mutant gene and its products operates at the transcriptional or translational level to quantitatively enhance protein synthesis or operates in- a protective fashion to block enzymatic degradation of proteins synthe¬ sized, the overall result is enhanced expression of protein synthesis in terms of greater net quantities of isolatable products of exogenous and endogenous gene directed protein synthesis.
The present invention additionally compre¬ hends improvements in prior methods for securing production, in 1__ coli host cells, of protein coded for by exogenous genes, which improvements comprise employing E^_ coli host cells which contain a chor osomal mutation in the capsular polysaccharide, capR (Ion) , gene. While preferred methods involve use of E^_ coli cells having the above-noted dominant mucoid mutant allele (especially the capR9 allele) , also comprehended is the use of cells carrying other capR mutations, including recessive mutations. An example of the practice of this improved methodology is provided by the following description of work performed by collaborators Donald F. Steiner and Shu Jin Chan on E^ coli host cell strains which differed from each other, inter alia, in terms of the presence or absence of a putatatively recessive chromosomal mutation iri the capR (Ion) gene.
EXAMPLE 3
Parallel experiments were carried out according to Example 2 using as« a transformation vector the PEX2 plasmid containing a rat proinsulin gene. In the first experiment the host was E^ coli K-12, strain 3343 (F , thi, cys, lys, xyl, mtl, mal, strA, lacZ, ptr-3) . The ptr-3 mutation is a mutation in a protease-directing gene other than capR [Cheng, et a _, J. Bacteriol. , 140, pp. 125-130 (1979)]. The host strain for the second experiment was E_ coli
K-12, strain 3325 [F~, strA, nalA, lacZ, ptr-3, lon-rl
(also referred to as deg-rl) . See, Gottesman, et al.,J. Bacteriol., 133, pp. 844-851 (1978)].
Radioimmunoassays for rat proinsulin were carried out according to the procedures noted in Example 2. No rat proinsulin production was detected in the host cells of the first experiment. Rat proinsulin was detected in the host cells of the second experiment, wherein the host strain carried a mutation in the capR
(Ion) gene.
Numerous modifications and variations in the practice of the invention as described above are expected to occur to those skilled in the art.
Therefore, only such limitations as appear in the appended claims should be placed on the invention.
OMPI

Claims

WHAT IS CLAIMED IS:
1. A method for enhancing expression of exogenous gene directed protein synthesis in Escherichia coli cells having an exogenous gene incorporated therein, said method comprising the step of genetically transforming the cells to incorporate a dominant mucoid mutant allele of the capsular polysaccharide, capR, gene.
2. A method according to Claim 1 wherein said dominant mucoid mutant allele is the capR9 allele.
3. A method according to Claim 1 wherein said transforming step comprises transformation with the DNA Plasmid pBZ201M9 (A.T.C.C. Plasmid No. 40041).
4. In the method for producing, in
Escherichia coli cells, a protein coded for by a selected exogenous gene, the improvement comprising:
(a) genetically transforming the cells to incorporate said selected exogenous gene; (b) genetically transforming cells to incorporate a dominant mucoid mutant allele of the capsular polysaccharide, capR, gene;
(c) propagating cells transformed according to steps (a) and (b) ; and (d) isolating protein coded for by said selected exogenous gene and produced by cells propagated according to step (c) .
5. The improvement of Claim 4 wherein said dominant mucoid mutant allele is the capR9 allele.
6. The improvement of Claim 4 wherein step
(b) is carried out using the DNA plasmid pBZ201M9
(A.T.C.C. Plasmid No. 40041).
7. The improvement of Claim 4 wherein steps (a) and (b) are carried out using a single transformation vector including both said selected exogenous gene and said dominant mucoid mutant allele.
8. The improvement of Claim 7 wherein said dominant mucoid mutant allele is the capR9 allele.
9. The improvement of Claim 7 wherein said single transformation vector is DNA plasmid pBZ201M9 (A.T.C.C. Plasmid No. 40041) which has been hybridized to include said selected exogenous gene.
10. A protein product synthesized by and isolated from Eschericha coli cells according to the improved method of Claim 4.
11. A method of enhancing expression of endogenous gene directed protein synthesis in Eschericha coli cells, said method comprising the step of genetically transforming the cells to incorporate a plasmid including a dominant mucoid mutant allele of the capsular polysaccharide, capR, gene.
12. A method according to Claim 11 wherein said dominant mucoid mutant allele is the capR9 allele.
13. A method according to Claim 11 wherein said transforming step comprises transformation with the DNA Plasmid pBZ201M9 (A.T.C.C. Plasmid No. 40041) .
OMPI
PCT/US1982/001075 1981-08-21 1982-08-09 Enhancement of expression of protein synthesis in e. coli WO1983000702A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29512181A 1981-08-21 1981-08-21
US295,121810821 1981-08-21

Publications (1)

Publication Number Publication Date
WO1983000702A1 true WO1983000702A1 (en) 1983-03-03

Family

ID=23136297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1982/001075 WO1983000702A1 (en) 1981-08-21 1982-08-09 Enhancement of expression of protein synthesis in e. coli

Country Status (3)

Country Link
EP (1) EP0093121A4 (en)
JP (1) JPS58501406A (en)
WO (1) WO1983000702A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174367A1 (en) * 1984-03-06 1986-03-19 Harvard College Hosts and methods for producing recombinant products in high yields.
US4663281A (en) * 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
EP0227260A1 (en) * 1985-10-25 1987-07-01 Omnigene Inc Enhancing the expression of genes in microorganisms
EP0528955A1 (en) * 1990-05-02 1993-03-03 Gen Hospital Corp Protease deficient bacterial hosts.
US5665578A (en) * 1986-03-07 1997-09-09 Gillies; Stephen D. Vector and method for achieving high level of expression in eukaryotic cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329448A (en) * 1979-07-10 1982-05-11 Lever Brothers Company Microbial heteropolysaccharide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329448A (en) * 1979-07-10 1982-05-11 Lever Brothers Company Microbial heteropolysaccharide

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
J. Bacteriology Vol 127 No. 3 pp. 1208-1216 (1976). *
J. Bacteriology Vol 133 No. 2 pp. 844-851 (1978). *
J. Bacteriology Vol 143 No. 2 pp. 852-863 (Aug. 1980). *
J. Bacteriology Vol 147 No. 1 pp 46-56 (July 1981). *
J. Bacteriology Vol. 129 No. 1 pp. 358-366 (1977). *
Molec. Gen. Genet. 175, pp. 325-332 (1979). *
See also references of EP0093121A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174367A1 (en) * 1984-03-06 1986-03-19 Harvard College Hosts and methods for producing recombinant products in high yields.
US4758512A (en) * 1984-03-06 1988-07-19 President And Fellows Of Harvard College Hosts and methods for producing recombinant products in high yields
EP0174367A4 (en) * 1984-03-06 1988-08-29 Harvard College Hosts and methods for producing recombinant products in high yields.
US4663281A (en) * 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
EP0227260A1 (en) * 1985-10-25 1987-07-01 Omnigene Inc Enhancing the expression of genes in microorganisms
US5017477A (en) * 1985-10-25 1991-05-21 Biotechnica International, Inc. Enhancing DNA sequencies derived from the sacQ gene
US5665578A (en) * 1986-03-07 1997-09-09 Gillies; Stephen D. Vector and method for achieving high level of expression in eukaryotic cells
EP0528955A1 (en) * 1990-05-02 1993-03-03 Gen Hospital Corp Protease deficient bacterial hosts.
EP0528955A4 (en) * 1990-05-02 1993-06-16 The General Hospital Corporation Protease deficient bacterial hosts

Also Published As

Publication number Publication date
EP0093121A1 (en) 1983-11-09
EP0093121A4 (en) 1984-02-09
JPS58501406A (en) 1983-08-25

Similar Documents

Publication Publication Date Title
Okada et al. Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers
EP0356739B1 (en) Recombinant DNA, microorganism carrying said recombinant DNA, and process for producing L-amino acids by the use of said microorganism
CA1266628A (en) Manufacture and expression of structural genes
JP2608870B2 (en) Production of human IGF by recombinant DNA technology
RU2072393C1 (en) Method for obtaining recombination polypeptide possessing growth hormone properties
Bankaitis et al. Proper interaction between at least two components is required for efficient export of proteins to the Escherichia coli cell envelope
US4713337A (en) Method for deletion of a gene from a bacteria
EP0856059A1 (en) Methods for production of recombinant plasmids
WO1984004535A1 (en) Heat regulated production of selected and fused proteins in yeast
Burns et al. Evolution of the tryptophan synthetase of fungi. Analysis of experimentally fused Escherichia coli tryptophan synthetase alpha and beta chains.
EP0077196A2 (en) Aromatic amino acid-producing microorganisms
US4590159A (en) Enhancement of expression of protein synthesis in E. coli
Capuano et al. An in vivo approach to define the role of the LCM, the key polypeptide of cyanobacterial phycobilisomes.
EP0026598A1 (en) DNA transfer vectors for human proinsulin and human pre-proinsulin, microorganisms transformed thereby, and processes involving such substances
WO1983000702A1 (en) Enhancement of expression of protein synthesis in e. coli
EP0449839A1 (en) Improved bacterial strains for heterologous gene expression
Vasil et al. Regulation of exotoxin A synthesis in Pseudomonas aeruginosa: characterization of toxA‐lacZ fusions in wild‐type and mutant strains
US4772555A (en) Dedicated ribosomes and their use
Moriya et al. Cloning and characterization of the hrpA gene in the terC region of Escherichia coil that is highly similar to the DEAH family RNA helicase genes of Saccharomyces cerevisiae
EP0648836B1 (en) MHC class II transactivator (CIITA) and uses thereof
Stuitje et al. The nucleotide sequence surrounding the replication origin of the cop3 mutant of the bacterio-cinogenic plasmid Clo DF13
Temple et al. Analysis of cloned structural and regulatory genes for carbohydrate utilization in Pseudomonas aeruginosa PAO
JPH11514885A (en) Chitin synthase 1
US4977089A (en) Vector comprising signal peptide-encoding DNA for use in Bacillus and other microorganisms
AU599574B2 (en) Recombinant saccharomyces

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1982902784

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1982902784

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1982902784

Country of ref document: EP